Drug intelligence / Profile preview

FEC3-D3

Development stage: Unknown
Modality: Small Molecules
Administration: Intravenous

Overview

FEC3-D3 is a neoadjuvant chemotherapy regimen used primarily for the treatment of node-positive breast cancer. This regimen consists of three cycles of FEC (Fluorouracil, Epirubicin, and Cyclophosphamide) followed by three cycles of Docetaxel. It is designed to provide comparable efficacy with a shorter duration compared to other regimens, aiming to reduce tumor size before surgery and improve patient outcomes. The individual components work through various mechanisms to disrupt cancer cell proliferation and induce cell death.

Other names: Neo-shorterFEC-D

Targets

TOP2A (DNA topoisomerase II)TS (Thymidylate synthase)TUBB (Tubulin (alpha and beta subunits))DNA

Beyond the preview

Go deeper on FEC3-D3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FEC3-D3.

Explore the full profile